What’s being tested
Psilocybin for Chronic Pelvic Pain in Women: A Pilot Feasibility Study
Bottom line: A pilot study is exploring whether psilocybin combined with psychotherapy may be safely delivered to women with chronic pelvic pain who haven’t responded to standard treatments.
A new trial is testing whether a single dose of psilocybin, combined with psychotherapy, could be a safe and feasible option for women with chronic pelvic pain who haven’t found relief from standard treatments. This study is still in its early stages — but it’s raising important questions about how such an intervention might be delivered.
This trial is exploring whether a single dose of pharmaceutical-grade psilocybin (25 mg), given with structured psychotherapy, is safe and feasible for women with chronic pelvic pain (CPP) that hasn’t responded to conventional options. The study is not yet looking at whether the treatment works — it’s focused on whether it can be delivered safely to 15 women and whether they can complete the process.
The design at a glance
This is a Phase 1 trial, currently recruiting participants, sponsored by Oregon Health and Science University. Phase 1 trials are about safety, dosage, and how an intervention is delivered, not about proving that it works. The study includes 15 women with CPP who haven’t found relief from standard treatments. Each participant will receive a single dose of psilocybin (25 mg) along with two preparatory psychotherapy sessions before the dose and three integration sessions afterward. The goal is to collect early safety data and assess how well the intervention can be implemented.
Why it matters
Chronic pelvic pain can have lasting physical and emotional effects, and it’s often difficult to treat. If this trial shows that the approach is safe and can be delivered, it could point the way to new treatments for a condition that often lacks effective options. This trial is asking a question — not yet answering it — but it’s an important step in the right direction.
What this does NOT mean yet
This is a pilot study, and no results have been published or made public. The trial is still recruiting and hasn’t yet reached its conclusion. Just because a trial is registered doesn’t mean the intervention is safe, effective, or endorsed by any authority. Many trials don’t meet their goals, and the results of this study will only be known once the trial is complete and the data is analyzed. At this stage, the trial is asking a question, not answering it.
How to follow it
You can track the progress of this trial through the ClinicalTrials.gov record at NCT06988319. This is where updates, participant numbers, and eventual results will be posted.
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
